Di'an Diagnostics and Shaw Yee Hospital have reached a cooperation agreement to jointly promote the transformation of medical achievements related to immunotherapy biomarkers for liver cell carcinoma.

On September 11th, Dean Diagnostic Technology Group Co., Ltd. and Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, signed a contract to complete the transformation project "Method and Application of Constructing a Genetic Model for Identifying a New Subtype of Hepatocellular Carcinoma" to jointly promote the transformation of medical achievements related to immunotherapy markers for liver cancer. The focus of this transformation is to use omics and AI technology to construct an HCC new subtype identification model based on 29 genes. Patients with this subtype have a significantly higher immunotherapy response rate than non-HCC-1 subtype patients. This achievement helps in screening potential immunotherapy beneficiaries, avoiding ineffective treatment, and saving medical resources. Currently, a nationwide multicenter study based on this project is underway.